CD274 and colorectal carcinoma: A combination of DAC with NY-ESO-1-specific TCR-T cells was suggested as an innovative synergistic therapeutic strategy with a significant effect in CRC treatment [39].Therefore, the main aim of our study is to investigate the effect of DAC on immune-related molecules, PD-L1, NY-ESO-1, and on stemness markers in the primary 1076 Col and the metastatic 1872 Col cells to understand its role as a therapeutic agent for CRC.